Engimmune Therapeutics
Platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on T cell receptor (TCR) targeting solid tumours
Basel, Switzerland
Total raised
€16M
€15,514,556
Funding rounds
2
Investors
3
distinct backers
Active since
2022-02
latest 2022-05
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood18
base rate 44% for Seed
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood12
base rate 12% (2+ rounds)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-05-03 | Seed | €15M | Novo Holdings,Pureos Bioventures | View deal → |
| 2022-02-21 | Other | €483k | BaseLaunch | View deal → |
Related news
- Engimmune Therapeutics raises CHF 15.5 million in seed financingstartupticker.ch · 2022-05
- BaseLaunch invests USD 1.5 million in three new startupsstartupticker.ch · 2022-02
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy